Array BioPharma will soon be entering a pivotal trial for its wholly owned blood cancer drug and investors should know its outlook by the end of 2014, says the company's CEO Ron Squarer. Array is also partnering with AstraZeneca and Novartis on a number of other cancer drugs with trials soon getting underway that could transform the company by year end. Squarer says Array is superior at smaller, faster hematology studies, while partnerships work better for larger projects, and he is not giving away the store when teaming up with the likes of Celgene.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: I Remain Constructive on Micron Shares

Jim Cramer: I Remain Constructive on Micron Shares

Video: Jim Cramer on Why the Market Opened Lower on Wednesday

Video: Jim Cramer on Why the Market Opened Lower on Wednesday